The Inflation Reduction Act included some very significant changes to the ways in which the Medicare program handles drug pricing.
Among the changes are a redesign of the Medicare Part D (prescription drug benefit) program, as well as requirements that certain drug prices be negotiated with the Centers for Medicare & Medicaid Services and a provision that drug manufacturers pay inflation rebates to on utilization of drugs covered by Medicare Part B and Part D in certain circumstances.
To address these changes to the law, Reed Smith has put together a series of alerts and webinars on the topics.
Reed Smith alerts on changes to the law
In an effort to make sense of these new provisions, Reed Smith health lawyers Joseph W. Metro, Robert J. Hill, James F. Segroves, Andrew Y. Lu, Andrew R. Hayes, and Lois Sheng Liu have written a series of alerts analyzing the most major changes in the law.
The alerts are:
- Part I: New Medicare Inflation Rebates Take Effect Within Months
- Part II: Limits on Insulin Cost-Sharing under Medicare Parts B and D
- Part III: Medicare Part D Benefit, Subsidy, and Manufacturer Discount Redesign
Webinar series highlights essential information
In addition, the same experts are also holding a series of webinars on the changes to the law. The next webinar is being held on Sept. 29 at noon EST on the topic of Medicare Part D redesign.
The webinar on the Medicare program’s newly acquired ability to “negotiate” certain drug prices will be held on Oct. 4 at noon EST.
The registration link for the webinars can be found here. All of the webinars are available for CLE credit in certain jurisdictions and all are free and open to the public
Reed Smith will continue to track developments related to the Inflation Reduction Act and Medicare Drug Pricing. If you have any questions or would like more information, please reach out to the Reed Smith health lawyers mentioned above for help.